Clinical and economic burden of comorbid coronary artery disease in patients with acute exacerbation of chronic obstructive pulmonary disease: sex differences in a nationwide cohort study

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide that induces a considerable economic and social burden [1]. Comorbidities are common at any severity of COPD that may have a significant impact on disease process [1]. Among hospitalized population with an acute exacerbation of COPD (AECOPD) and severe airflow limitation, severe coronary artery disease (CAD) is present in about one-third of patients [2]. Moreover, patients with reduced lung function are at higher risk of developing CAD [3]. Early identification and proper management of these patients might improve the prognosis and reduce the risk of death.

Patients with COPD and CAD have specific clinical characteristics including more frequent respiratory symptoms, worse health status, and higher medication expenditure [4‐6]. However, researches about the impact of comorbid CAD on clinical outcomes in AECOPD patients are limited. A single center historical cohort study including 507 separate hospital admissions for AECOPD reported that comorbid CAD was associated with longer length of stay, greater risk of intensive care unit (ICU) admission, and death [7]. This study has a relatively small sample size and did not investigate the impact of CAD on symptoms, economic burden of hospitalization, and future exacerbations or mortality among AECOPD patients.

Many studies have shown differences between men and women regarding the prevalence and clinical characteristics of comorbidities such as cardiovascular disease (CVD), bronchiectasis, and metabolic syndrome in COPD [8‐10]. A multicenter study of patients hospitalized for COPD exacerbations showed that women had a lower prevalence of CAD but presented more chronic heart failure [11]. Instead, a 10-year study in subjects hospitalized due to COPD in Beijing reported that the prevalence of CAD decreased with years in men but increased in women, and reached to be similar between men and women at the end of the study [12]. The burden of CAD in the current Chinese AECOPD population remains unclear. Furthermore, scarce data exist in analyzing the sex-related differences in AECOPD outcomes according to the presence or absence of CAD.

This multicenter real-world study aimed to investigate the predictors of comorbid CAD in AECOPD patients according to sex and assess the effect of CAD on the length of hospital stay, healthcare costs, and change of symptom score during hospitalization in men and women among patients admitted for AECOPD. We additionally aimed to study whether the contribution of comorbid CAD to symptoms and readmissions or death within 30 days after discharge differed by sex and explore the factors associated with readmissions or death after 30 days.

To the best of our knowledge, this is the first and largest study using real-world data to investigate sex differences in AECOPD outcomes according to the presence or absence of CAD. We found that 17.0% of patients admitted with AECOPD had concomitant CAD and this frequency was higher in women in our study. The predictors of comorbid CAD showed obvious sex difference. In addition, only in men, comorbid CAD was associated with a longer length of hospital stay and higher total cost. For women, comorbid CAD did not significantly influence the clinical outcomes. Sex and CAD were not relevant to readmissions or death within 30 days after discharge.

COPD characterized by low-grade systemic inflammation plays a role in the development or acceleration of CVD [17]. A large meta-analysis reported that COPD patients had a two times higher risk of CAD [18]. However, CAD prevalence rates in COPD patients range from 3 to 64% [18], partly due to the different severity of COPD and also because pulmonary symptoms can mimic and mask the symptoms of CVD leading to misdiagnosis or missed diagnosis. Although studies have showed that exacerbations confer an increased risk of subsequent cardiovascular events [19], data about the prevalence of CAD in AECOPD are limited. The prevalence rate in this study was similar to 17.0% reported by Almagro et al. [11], but lower than 28.8% reported by Aliyali et al. who recruited older participants aged over 50 in their study [7]. Contrary to the results found by Almagro et al. [11], the prevalence of CAD in our study was higher in women than in men. This might be related to insufficient pre-admission treatment in women including the use of LABA and home oxygen therapy acting as protective factors against comorbid CAD. In fact, a study in hospitalized COPD patients in China has reported that for CAD, the prevalence in men decreased and that for women increased year by year, which could be partly explained by the increase of occupational exposure and social or psychological stress in women [12].

Common cardiovascular risk factors including age, BMI, hypertension, and diabetes were also independently associated with the prevalence of CAD in men admitted for AECOPD in our study. The results were in line with the findings of Bellocchia et al. that age and BMI were predictive factors of CAD, although their study recruited patients with stable COPD [20]. In addition, both hypertension and diabetes can cause structural alterations of lung and heart tissue due to systemic inflammation or oxidative stress, which were highly associated not only with the development of CVD but also with the pathogenesis of COPD [21]. Moreover, cerebrovascular disease and other types of CVD might be independently associated with comorbid CAD considering a number of shared risk factors (e.g., age and obesity) between them.

In women, the role of BMI, cerebrovascular disease, and diabetes became less important when assessing the risk of comorbid CAD. Similarly, a large study based on 2046 stable COPD patients reported that in men, age, BMI, smoking status, mMRC, energy, and pulmonary function were related to cardiac disease, while in women the predictors only included age [8]. Of note, we found pre-admission use of LABA and home oxygen therapy were protective factors against comorbid CAD in women but showed no relationship with comorbid CAD in men. Although evidence for the safety of LABA in patients with concomitant COPD and CVD is less definitive, many studies including randomized controlled trials and post-hoc analyses have concluded that LABA administration does not increase the risk of cardiovascular events in patients with COPD [22, 23]. There are also data suggesting that LABA can produce a positive impact on reducing the risk of CVD. An interventional, randomized, double-blind clinical trial showed that a clinically relevant improvement of dyspnea with indacaterol was associated with a significant increase of the right ventricular compliance indexes [24]. Inhaled LABA also had direct benefits on pulmonary haemodynamics [25] and reduced exacerbations in COPD patients [26], which could lead to an increased risk of CVD [19]. The reason for different roles of LABA in men and women was not clear but might be partly explained by the sex differences in response to LABA.

In our study, comorbid CAD was associated with poorer short-term outcomes. This was consistent with previous studies. Aliyali et al. reported that the median length of stay was 7 days in patients with CAD versus 6 days for patients without CAD and the adjusted odds ratio for the risk of ICU admission in patients with CAD was 2.97 [7]. Another study analyzing stable-state data of 386 subjects from the London COPD Cohort showed that patients with CAD had significantly worse health status, lower exercise capacity, and more dyspnea as well as longer exacerbations [5]. However, as far as we know, no research has investigated the sex-related differences in the effect of comorbid CAD on AECOPD outcomes. We found that only in men, comorbid CAD was associated with a higher rate of ICU admission and longer length of hospital stay. The following reasons may account for the poorer outcomes in men with CAD. For the population in the ACURE study, only in men, patients with CAD had a higher level of NT-proBNP proposed as a marker of left ventricular and endothelial dysfunction and early mortality in patients with AECOPD [27]. The proportion of patients prescribed SABD during hospitalization was significantly lower in men with CAD than those without. Less use of SABDs, which were recommended as the initial bronchodilators for AECOPD [1], could result in inadequate symptom control.

Several studies demonstrated a substantial economic burden associated with comorbid CVD among COPD patients. In a nationally representative population of COPD adults in the United States, presence of CVD was associated with higher annual healthcare expenditure and resource utilization [28]. A population study using health administrative data for over 7 million people in Canada reported that individuals with COPD had more health service claims including higher claim rates of emergency department visits and hospitalizations for CVD compared to the general population [29].

The impact of comorbid CAD on the economic burden during an AECOPD and whether it differs by sex remain unclear. Our study showed that patients with CAD had a higher economic burden of hospitalization than those without CAD, but the difference was significant only in men. In particular, accounting for the highest proportion of total cost, medicine fee was also numerically higher in men with CAD. This might be related to their serious conditions indicated by the higher rate of ICU admission and longer length of hospital stay.

In our analyses, COPD symptoms assessed by the CAT score and mMRC dyspnea grade were more severe in patients with CAD at day 30, especially in men with CAD, although the decreases of CAT score during hospitalization were more significant among patients with CAD. No relationship was found between comorbid CAD and all-cause readmission or death or AECOPD readmission within 30 days regardless of sex. To our best knowledge, there is no relevant research comparing the risk of readmission or death after 30 days between AECOPD patients with and without comorbid CAD.

A prospective observational study in 2887 COPD patients enrolled from primary care claimed that there was no difference in the annualized rate of AECOPD and mortality between those with or without CVD during the 24-month follow-up period and sensitivity analyses for each CVD diagnosis also did not show any relationship between individual CVD and the incidence of exacerbations [30]. Patel et al. recruiting patients from the London COPD Cohort conducted a prospective evaluation of exacerbations in those who had completed symptom diaries for ≥ 1 year and reported a longer duration but not an increased frequency of AECOPD in patients with CAD [5]. However, when the follow-up period was extended to more than 5 years, data from two population-based cohorts showed that the presence of respiratory impairment and comorbid CVD predicted higher mortality and higher risk of all-cause hospitalization [31]. In addition, in our real-world study with relatively recent recruitment of AECOPD patients, variables associated with a higher risk of 30-day readmission or death were frequent hospitalizations and lower FEV₁% predicted.

Indeed, data on differences between the sexes in COPD with comorbidities are scarce. In patients with COPD, it has been suggested that there are substantial differences between men and women in airway anatomy, with women exhibiting smaller lumina and disproportionately thicker airway walls than men [32]. Furthermore, important differences in biology, genetic susceptibility to airway damage, and lung microbiome have been reported [33]. These differences between men and women with COPD may have a role in differently influencing the characteristics of COPD comorbidities. In fact, the protective role of estrogens in regulating the contractility of airway smooth muscles [34] and in the cardiovascular system [35] probably reduces the adverse effects of comorbid CAD on women. The potential differences in prognosis and complicated mechanisms need to be further studied.

The strength of our study was that we used real-world data from the ACURE study which was the first and largest registry of hospitalized AECOPD patients in China. Our analyses provided a comprehensive overview of the clinical characteristics and outcomes of in-hospital AECOPD patients. Moreover, all patients had a diagnosis of COPD confirmed by spirometry at baseline. This study also had several limitations. First, data on treatments for CAD before and during hospitalization were unavailable in the ACURE study, which could also affect clinical outcomes. Second, patients in our study might be admitted to the hospital at different periods of their exacerbations and there was no accurate data regarding when their symptoms started. Some patients might be admitted earlier in their exacerbation course, which potentially confounded the results. However, this real-world study reflected the realities of patients requiring hospitalization and provided valuable information for clinical practice. Such data collection will be planned in our future studies. Third, there were missing data (e.g., blood gas) in a portion of patients. Fourth, not all patients in our study had follow-up data within 30 days after discharge. However, the baseline characteristics were largely similar between those with or without follow-up data, making selective bias less likely. Finally, no long-term prognostic analysis was performed because the ACURE study is still ongoing with only the 30-day data available.

Using data from a large AECOPD cohort, we revealed the different role of clinical characteristics in men and women in evaluating the risk of comorbid CAD. For men hospitalized for AECOPD, comorbid CAD was associated with a higher rate of ICU admission, longer length of hospital stay, higher economic burden of hospitalization, and more severe COPD symptoms at day 30. No significant difference was found in women. Comorbid CAD showed no relationship with 30-day readmission or death regardless of sex. Clinicians should have heightened attention for men with comorbid CAD to achieve an optimal management of AECOPD patients.